Evidence map›Paper›PMID 35657919›Full record

ArticlePloS one2022

A mathematical model of in vitro hepatocellular cholesterol and lipoprotein metabolism for hyperlipidemia therapy.

Yuri Efremov, Anastasia Ermolaeva, Georgiy Vladimirov, Susanna Gordleeva, Andrey Svistunov, Alexey Zaikin, Peter Timashev

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Yuri EfremovInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID 0000-0001-7040-253X
Anastasia ErmolaevaWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov University, Moscow, Russia.ORCID 0000-0002-9513-7434
Georgiy VladimirovInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Susanna GordleevaLobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Andrey SvistunovSechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Alexey ZaikinLobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Peter TimashevInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Sechenov University · RUInnopolis University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases associated with high cholesterol (hypercholesterolemia) and low-density lipoproteins (LDL) levels are significant contributors to total mortality in developing and developed countries. Mathematical modeling of LDL metabolism is an important step in the development of drugs for hypercholesterolemia. The aim of this work was to develop and to analyze an integrated mathematical model of cholesterol metabolism in liver cells and its interaction with two types of drugs, statins and PCSK9 inhibitors. The model consisted of 21 ordinary differential equations (ODE) describing cholesterol biosynthesis and lipoprotein endocytosis in liver cells in vitro. The model was tested for its ability to mimic known biochemical effects of familial hypercholesterolemia, statin therapy, and PCSK9 inhibitors. The model qualitatively reproduced the well-known biology of cholesterol regulation, which confirms its potential for minimizing cellular research in initial testing of new drugs for cardiology.

Indexed as

Anticholesteremic AgentsCarcinoma, HepatocellularHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHyperlipidemiasLiver NeoplasmsAntibodies, MonoclonalCholesterolCholesterol, LDLHumansLipoproteinsModels, TheoreticalPCSK9 InhibitorsProprotein Convertase 9Antibodies, MonoclonalAnticholesteremic AgentsCholesterolCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteinsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Identifiers

PMID35657919
PMCPMC9165868
OpenAlexW4281677783

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.